Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LENALIDOMIDE vs POMBILITI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes associated with deletion 5q,Mantle cell lymphoma (relapsed or refractory)
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
500 mg orally twice daily
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Metabolized via hydrolysis and glucuronidation; CYP450 enzymes play a minor role.
Primarily metabolized by CYP3A4, CYP2C8, and CYP2C9; also undergoes glucuronidation. The active metabolite, GFT505, is formed via hydrolysis.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
~30% bound, primarily to albumin.
>99% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating distribution into total body water.
Volume of distribution is approximately 2000 L (>25 L/kg), indicating extensive extravascular distribution and tissue binding.
Oral: ~80% (range 60-100%); food does not significantly affect absorption.
Oral bioavailability is approximately 25% (range 15–35%) due to first-pass metabolism; may increase with high-fat meal.
For Cr Cl 30-60 m L/min: 5 mg once daily; for Cr Cl <30 m L/min not requiring dialysis: 2.5 mg once daily; for Cr Cl <30 m L/min requiring dialysis: 2.5 mg once daily post-dialysis on dialysis days.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 250 mg twice daily; GFR <15 m L/min or dialysis: 250 mg once daily
No specific dose adjustment for hepatic impairment in FDA labeling; use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended
Not approved in pediatric patients; safety and efficacy not established in patients <18 years.
Weight <40 kg: 10 mg/kg orally twice daily (max 500 mg/dose); Weight ≥40 kg: 500 mg twice daily
No specific dose adjustment beyond renal function; monitor for hematologic toxicity and thromboembolic events due to age-related comorbidities and renal impairment.
No specific adjustment required; monitor renal function and consider age-related decline in GFR
Embryo-fetal toxicity: Can cause fetal harm. Do not use during pregnancy. Females of reproductive potential must use contraception or abstain. Hematologic toxicity: Significant neutropenia and thrombocytopenia; monitor blood counts. Deep vein thrombosis and pulmonary embolism: Increased risk; monitor and consider prophylaxis.
None.
Hematologic toxicity (neutropenia and thrombocytopenia); thromboembolic events; hepatotoxicity; allergic reactions; tumor lysis syndrome; thyroid disorders; neuropathy; increased risk of second primary malignancies.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests before and during treatment.,Myopathy: Risk of muscle injury; assess creatine kinase if muscle symptoms occur.,Gallbladder-related events: Increased risk of cholelithiasis and cholecystitis.,Fetal risk: Based on animal data, may cause fetal harm; advise effective contraception in females of reproductive potential.,Renal impairment: Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Pregnancy; hypersensitivity to lenalidomide; concomitant use with live vaccines; breastfeeding not recommended.
Hypersensitivity to elafibranor or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) as they inhibit CYP3A4 and may increase lenalidomide exposure. No other significant food interactions. Take capsules with water; do not crush or chew.
No known food interactions. Maintain a balanced diet as recommended by a healthcare provider. There are no specific dietary restrictions required with Pombiliti.
Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects, cardiac anomalies) and fetal death. No adequate studies in second or third trimester, but risk persists throughout pregnancy. Contraindicated in pregnancy.
Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show embryolethality and teratogenicity at subclinical doses.
No data on lenalidomide in human milk; however, due to potential for serious adverse effects in nursing infants (including neutropenia and thrombocytopenia), breastfeeding is contraindicated during therapy and for at least 1 week after last dose. M/P ratio unknown.
No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression, myelosuppression), breastfeeding is not recommended during therapy and for at least 3 months after last dose.
Lenalidomide is contraindicated in pregnancy; no dose adjustments are recommended because use is prohibited. No pharmacokinetic studies in pregnancy; however, physiological changes (e.g., increased volume of distribution, renal clearance) may alter drug levels, but given teratogenicity, dosing is not applicable.
No dose adjustment recommendations are possible; Pombiliti is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not studied due to contraindication. No specific dosing guidelines exist for pregnant patients.
Lenalidomide is an immunomodulatory drug (IMi D) with anti-angiogenic and anti-proliferative properties. It requires risk evaluation and mitigation strategy (REMS) due to teratogenicity. Monitor for thromboembolic events (DVT/PE) especially when combined with dexamethasone. Consider dose adjustment for renal impairment (Cr Cl < 60 m L/min). Baseline and periodic monitoring of CBC, thyroid function, and liver enzymes is essential. May cause tumor lysis syndrome in high tumor burden patients; ensure hydration and prophylaxis.
Pombiliti (cipaglucosidase alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy for Pompe disease. Do not confuse with alglucosidase alfa (Myozyme/Lumizyme). Requires premedication with antihistamines and antipyretics due to risk of infusion-associated reactions (IARs). Monitor for anaphylaxis, particularly during initial infusions. Administer by IV infusion over approximately 4 hours. Use a low-protein-binding infusion set with an in-line low-protein-binding filter. May cause rapid deterioration in patients with cardiac hypertrophy; monitor cardiac function before and during treatment.
Do not take lenalidomide if you are pregnant, breastfeeding, or planning to become pregnant; use two reliable forms of contraception during treatment and for 4 weeks after stopping.,Do not donate blood or sperm while taking lenalidomide and for 4 weeks after discontinuation.,Report any symptoms of blood clots (swelling, pain, redness in leg, sudden chest pain, shortness of breath) or signs of infection (fever, chills) immediately.,Take lenalidomide exactly as prescribed, usually once daily with a glass of water; do not break, chew, or open capsules.,Avoid grapefruit, grapefruit juice, and Seville oranges as they may affect drug metabolism.,Keep all appointments for blood tests to monitor for low blood cell counts and other side effects.
Inform your healthcare provider immediately if you experience hives, itching, difficulty breathing, swelling, chest tightness, or fever during or after the infusion.,You may receive premedications (such as antihistamines and acetaminophen) before your infusion to reduce the risk of allergic reactions.,Do not miss your scheduled infusions; regular treatment is necessary to manage Pompe disease.,Report any new or worsening muscle weakness, breathing difficulties, or heart-related symptoms.,Keep a list of all medications you take, including over-the-counter drugs and supplements, and share it with your doctor.,Pombiliti is not a cure; it is an enzyme replacement therapy to reduce symptoms and slow disease progression.
"The combination of lenalidomide and leflunomide may result in additive hematologic toxicity, particularly bone marrow suppression, due to overlapping mechanisms that impair hematopoietic cell proliferation and survival. Leflunomide, via its active metabolite teriflunomide, inhibits dihydroorotate dehydrogenase (DHODH) and suppresses pyrimidine synthesis in rapidly dividing cells, while lenalidomide modulates the ubiquitin E3 ligase cereblon, leading to altered cytokine production and direct antineoplastic effects. Clinically, patients may experience increased risks of severe neutropenia, thrombocytopenia, and anemia, potentially requiring dose reductions, growth factor support, or discontinuation of one agent."
"Digoxin, a cardiac glycoside, is a P-glycoprotein (P-gp) substrate. Lenalidomide, an immunomodulatory drug, can inhibit P-gp activity, leading to increased intestinal absorption and reduced renal clearance of digoxin. This interaction may cause elevated serum digoxin levels, increasing the risk of digoxin toxicity (e.g., arrhythmias, nausea, visual disturbances)."
"Lenalidomide, an immunomodulatory drug, increases the thrombogenic potential of Mestranol, an estrogen component of oral contraceptives, by enhancing platelet aggregation and endothelial activation. This combined prothrombotic effect elevates the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Patients, especially those with additional risk factors, require careful monitoring for signs of thrombosis."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LENALIDOMIDE vs POMBILITI, answered by our medical review team.
LENALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.. POMBILITI is a Immunomodulatory Agent that works by POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LENALIDOMIDE and POMBILITI depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LENALIDOMIDE is: 10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.. The standard adult dose of POMBILITI is: 500 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LENALIDOMIDE and POMBILITI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LENALIDOMIDE is classified as Category C. Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects,. POMBILITI is classified as Category C. Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.